RxDoctor Payments Data

Alex Minter, MD

Internal Medicine · San Diego, CANPI 1265588230

Payments from drug & device makers

$91,912in general payments, 2019–2025

Across 150 payments — averaging $612.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$89K
  • Novartis$329
  • Johnson & Johnson$270
  • E.r. Squibb & Sons, L.L.C.$223
  • Gilead$155
  • Amgen$128
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$2,87097%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$91,912 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$42,384
Medicare patients
219
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate25$431,515
PomalystPomalidomide18$403,349
NubeqaDarolutamide23$306,017
RevlimidLenalidomide21$290,733
IbrancePalbociclib13$208,836
Lenalidomide16$208,824
ImbruvicaIbrutinib11$181,598
Abiraterone Acetate38$92,475
EliquisApixaban28$23,301
Anastrozole220$4,229
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen58$1,231
Ondansetron Hcl86$986
Megestrol Acetate18$950
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$876
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$329$431,51525 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$223$403,34918 claims
BayerNubeqa$119$306,01723 claims
Bristol Myers SquibbRevlimid$89$290,73321 claims
PfizerIbrance, Eliquis$121$232,13741 claims
AbbVieSynthroid$26$57012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →